Finecure supplies 20+ international markets, including the United States, across South East Asia, Africa, the CIS and Latin America, backed by 100+ international product registrations. Products are available as branded distribution, generic supply or private label, with CTD, eCTD and ACTD dossiers formatted to the requirements of the destination market.
The portfolio comprises 254 commercialized formulations across seven therapeutic verticals. Each product page states the composition, dosage form, pharmacopoeial or in-house specification, pack and shelf life, so a distributor can assess suitability before making an enquiry rather than after it.
Manufacture is carried out at five WHO-GMP units. Oral solid dosage is produced at a USFDA-inspected OSD site with EIR issued; cephalosporin injectables at a separate inspected to PIC/S GMP standards facility; amoxicillin-clavulanate in a dedicated plant with a physically isolated block.
CTD / eCTD / ACTD dossiers, DMF support, CoPP and GMP certification per market.
Pharmacopoeial designation published per product, or in-house specification stated.
Commercial-scale capacity with GS1-compliant serialisation.
Regulatory affairs division monitoring USP, BP and EP standards for the destination market.